Abstract BACKGROUND: Collagen organization within tissues has a critical role in wound regeneration. Collagen fibril diameter, arrangements and maturity between connective tissue growth factor (CTGF) small interfering RNA (siRNA) and mismatch scrambled siRNA-treated wound were compared to evaluate the efficacy of CTGF siRNA as a future implement for scar preventive medicine. METHODS: Nanocomplexes of CTGF small interfering RNA (CTGF siRNA) with cell penetrating peptides (KALA and MPG
Introduction
Serious scars from major burns and surgery cause tremendous burden on individual patients, society and healthcare [1] . Long term physical dysfunction and psychological trauma left the patient in stigma. Current treatment options for scars have significant limitations. In present, mitomycin C and imiquimod have been employed as topical scar medications. In addition, bleomycin, interferon, botulinum toxin A and corticosteroids are prescribed as an intra lesional scar treatment. Triamcinolone acetonide (10-40 mg) injections every 3-4 weeks is one of the most prescribed treatment. However, well controlled double blind study could not prove the favorable scar preventive effect of these medications. In addition, corticosteroid injections cause many adverse effects such as hypo pigmentation and skin atrophy [2, 3] .
Scarring involves many aspects that are interrelated with multiple pathways. Tissue repair process is controlled by various peptides including cytokines and growth factors and these peptides are up-regulated after injury [4] [5] [6] . Scar tissue is formed by excess collagen synthesized by fibroblasts, in which regulatory cytokines are up-regulated after injury. CTGF functions as a key mediator in hyper-scarring formation after tissue injury [7] [8] [9] [10] . Prolonged over expression of CTGF has been associated with tissue fibrosis in human and down regulation CTGF could inhibit tissue fibrosis [11] [12] [13] . CTGF, a cystein-rich peptide (MW: 38 kDa) is excreted by fibroblasts, myofibroblasts and endothelial cells. CTGF is also over-expressed in keloid and hypertrophic scars [14, 15] .
Recently, gene silencing through siRNA has appeared as a promising approach [16] . siRNA holds promise in the study of gene expression by primary mammalian cells, and provides optimism for the potential future use of dsRNAmediated silencing in vivo to regulate normal and pathologic processes. However, siRNA cannot penetrate the plasma membrane due to its high molecular size (* 14,000 daltons) and the strong negative charge of the phosphate [17] . Due to very fast degradation of the 21-nt siRNA on cells in vitro, the application of siRNA in vivo may need chronic expression by an appropriate vector. The desirable siRNA delivery system should possess the capacity to protect siRNA from degradation and target to cell and release siRNA into the cytoplasm [18] .
In this study, peptide-based siRNA-mediated modification of CTGF and its implication in wound repair courses focusing on dermal collagen disposition and diameter was investigated. Collagen organization within tissues is a critical parameter that evaluates the efficacy of scar preventive therapies [19, 20] . To analyze the architecture of CTGF siRNA/KALA-treated full thickness skin wound as compared to mismatch siRNA-treated one, transmission electron microscopy (TEM) to measure the fibril diameters in skin at 0-8 wks post-wound. Changes in the homogeneity of fibril diameter were evaluated in relation with scarring. Comparison of fibril diameters, collagen arrangement and maturity between mismatch scrambled CTGF siRNA treatment groups and CTGF siRNA/KALA-treated groups were conducted aiming to evaluate the efficacy of CTGF siRNA as a future implement for scarless medication.
Materials and methods

Materials
All chemicals were purchased from Sigma chemicals (St.Louis, MO, USA). Human dermal fibroblast was provided from Dept. Dermatology, Seoul National University. CTGFsiRNA was purchased from Invitrogen Co., (Carlsbad, CA, USA). KALA and MPG-NLS were synthesized at Peptron Co. (Daejeon, Korea). KALA has an amino acid sequence of WEAKLAKALAKALAKHLAKALAKALK-ACEA. MPG-NLS has a single mutation on the second lysine residue of the nuclear localizing sequence (NLS) to serine (GALFLGFLGAAGSTMGAWSQPKSKRKV), was reported to abolish the nuclear translocation and facilitate a rapid release of the siRNA in the cytoplasm. DMEM (Dulbecco's Modified Eagle Medium) culture medium and FBS (fetal bovine serum) were purchased from Cellgro (Washington DC, USA), PS (penicillin streptomycin) was purchased from Gibco (Grand Island, NY, USA) and Cultrex Ò Rat collagen I was purchased from Trevigen (Geithersburg, MD, USA).
Cell lines
Primary human foreskin fibroblasts were kindly provided from dept. dermatology, medical school, Seoul National University. Fibroblasts were cultured in a 6 well plate (5 9 10 5 cells/well) in DMEM medium supplemented with 10% heat inactivated fetal bovine serum and 100 units/mL penicillin/streptomycin. Cells were maintained in a humidified atmosphere with 95% air and 5% CO 2 at 37°C.
Injury of human foreskin fibroblast in vitro
Previously reported in vitro wound model was employed [21] . In brief, cells were PBS washed and scratched with a sterile 100 lL plastic pipette. One line was scratched on confluent cultured human primary dermal fibroblast. After washing with PBS, cell media was replaced with complete media.
Preparation of CTGFsiRNA/peptide (KALA and MPG
DNLS
) and transfection
For CTGF siRNA delivery, siRNA/KALA or siRNA/ MPG DNLS complexes with different(N/P) ratios (1:1, 1:6, 1:12, and 1:24) were formed in OPTI-MEM reduced serum medium (Invitrogen, Carlsbad, CA) and incubated for 30 min at RT. In brief, CTGF siRNA (5 lL) was placed in vial first and add fusion peptide solution (KALA or MPG DNLS peptide (36 lg/3 ll) with 1.5 mL of 25 mM Naacetate buffer into the siRNA. The mixture was then vortexed and incubated for 30 min to form nano complexes. After 30 min incubation, cells grown to 60% confluence were then transfected with each siRNA-KALA or MPG DNLS (N/P ratio 1, 6, 12 and 24) complexes for 6 h. After 6 h incubation at 37°C, 2 mL of fresh DMEM supplemented with 10% FBS was added to the cells, without removing the overlay of carrier/siRNA.
CTGF small-interfering RNA (siRNA) and transfection
The siRNA molecules targeting CTGF (5 0 -UUAGCUCG-GUAUGUCUUCAUGCUGG-3
0 ) were complexed with tested peptides. Cells were plated in six-well plates at 1 9 10 5 cells/well, grown for 24 h then transfected with each 100 pmol siRNA for 6 h using lipofectamine and OPTI-MEMI reduced serum medium (Invitrogen, Carlsbad, CA, USA). Control cell were treated with StealthTM RNAi negative control duplex (Invitrogen, Carlsbad, CA, USA). One day before transfection, cells were plated in six-well plates at 1 9 10 5 cells/well. Cells should be 60-70% confluent at the time of transfection. For each transfection sample, Stealth TM RNAi-Lipofectamine TM 2000 complexes were prepared. After transfected with CTGF siRNA, cells were changed into the fresh medium with serum and incubated for another 18 h for maximum transfection efficiency. Then cells were PBS-washed and scratched as described previously [21] .
Immunoblot analysis
After 6 h (scratched), cells were rinsed with cold PBS, lysed in SDS-lysis buffer. Equal amounts of protein extracts in SDS-lysis buffer were subjected to 12% SDS-PAGE analysis and electrophoretically transferred to nitrocellulose membrane. Anti-CTGF antibody was purchased from Santa Cruz (Santa Cruz, CA, USA). b-actin antibody was from Sigma-Aldrich (St. Louis, MO, USA). Enhanced chemiluminescence (Amersham-Pharmacia, Buckinghamshire, U.K.) system was used for detection. Relative band intensities were determined by quantitation of each band with an Image Analyzer Gel Logic 200 Imaging System (Kodak, Rochester, NY, USA).
Measurement of collagen lattice contraction by fibroblasts
The control and siRNA/peptide modified cells were trypsinized and 0.2 mL of the cell suspension (containing 5 9 10 5 cells) was added to the dermal collagen solution, gently mixed and poured into a well of the six-well plate. Collagen lattices were allowed to gel for 60 min in a 5% CO 2 at 37°C. After 60 min, the collagen lattices were detached from the surface of the well by rimming the lattice with a sterile spatula. 4 mL of serum-free medium was added to each well and the rate of contraction was determined by measuring lattice diameter.
Preparation of whole thickness wound
New Zealand White rabbit (7-8 wks old; average body weight, 2.0 ± 0.2 kg) was employed as an animal model in this study [14] . Rabbits were anesthetized by ethyl ether inhalation (4-8 mL) for 30 s and rabbits became sedated. Full thickness biopsy punch wound model was prepared as reported previously [22] . In brief, four sites of full thickness excisional circular wounds (8 mm diameter) were created down to the cartilage on the peritoneal side of each ear employing 8 mm biopsy punch. And the punched area was cooled and disinfected with 5 mL of ice-cold 0.5% acrynol solution for 30 s. The inflicted animals were placed in fixant during the tested periods. Biopsy punch wound induced full thickness wound, in which epidermis, dermis and subcutaneous fat completely removed as shown in Scheme 1. To prevent infection, Cephadex (50 mg/kg) was injected subcutaneously daily. The animal experiments were performed under animal protocol number (2018-003-009) approved by the Duksung Women's University Institutional Animal Care and Use Committee.
Application of CTGF siRNA/peptide
nanocomplexes on wound sites
Each tested solutions was injected dermally into four different wound sites (9 4) with 10 lL injection volume at 1 h pre injury, 24 h, 48 and 96 h post injury time. Duoderm (Convatec Inc., Bridgewater, NJ, USA) dressings were applied at least 2-3 days for controlling exudates and blood. 
Histological observation
The skin specimens were excised and processed for histological evaluation at predetermined post injury time. On pre-determined post wounding time, the tested areas were excised and fixed in 10% neutral buffered formaldehyde solution, and paraffin embedded. Skin specimens were sectioned (5 lm) perpendicular to the surface and stained with hematoxylin and eosin. Collagen arrangements of dermal skin of rabbit ear at time was also investigated. Olympus microscope (Model BX 41, Tokyo, Japan) and image recording equipment (Models DP11 and PM 10SP, Tokyo, Japan) were employed.
Transmission electron microscopy (TEM)
For ultrastructural collagen analysis, normal skin and wound tissues were fixed overnight in a mixture of cold 2.5% glutaraldehyde in 0. Figure 1A shows Western blot analysis of CTGF expression in fibroblasts: no treatment, negative control, siRNA/ Lipofectamine, MPG DNLS only and siRNA/MPG DNLS (1:1, 1:6, 1:12 and 1:24) complexes treatment. As a negative and positive control, mismatch siRNA/Lipofectamine and CTGF siRNA/Lipofectamine were employed, respectively. The cell viability was tested by comparing actin levels in tested cells. An insignificant silencing effect was observed for naked siRNA as well as mismatch siRNA/Lipofectamine complexes. CTGF siRNA/MPG DNLS did not show significant down regulation of CTGF. Figure 1B shows Western blot analysis of CTGF expression on fibroblasts: no treatment, negative control, siRNA/lipofectamine, KALA only and siRNA/KALA (1:1, 1:6, 1:12 and 1:24) complexes treatment. As a negative and positive control, mismatch siRNA/Lipofectamine and CTGF siRNA/Lipofectamine were employed, respectively. A negligible silencing effect was shown for naked siRNA as well as mismatch siRNA/Lipofectamine complexes. CTGFsiRNA/KALA showed 40-60% down regulation (p \ 0.01) of CTGF at 1:12 and 1:24 ratios; KALA showed slightly higher down regulation of CTGF than Lipofetamine (p \ 0.01).
Collagen lattice contraction was inhibited
by CTGF siRNA/KALA nanocomplexes Downregulation of CTGF expression by siRNA transfection on the inhibition of collagen lattice contraction was evaluated by comparing time course of contraction of control and siRNA modified fibroblast populated collagen lattices. Figure 2A shows photographs of the collagen lattices after 48 h contraction by cultured fibroblasts. The lattices were modified by A: mismatch siRNA/lipofectamine, B: CTGF siRNA/lipofectamine, C: CTGF siRNA/ KALA, and D: CTGF siRNA/MPG DNLS . Figure 2B shows time course of contraction of collagen lattices for 96 h: to evaluate the ability of fibroblasts to contract collagen lattices, negative control(mismatch), siRNA/KALA, lipofectamine, MPG-modified cells were cast into floating collagen lattices and monitored contraction over time ( Fig. 2A) . Collagen lattices were rapidly contracted by transfected cells modified either with mismatch siRNA or CTGF siRNA/MPG DNLS from a starting diameter of 32mm to less than 18mm (56%) in the first 24 h; whereas lattices with CTGF siRNA/KALA-modified cells contracted from 32mm to 23mm (72%) in the first 24h. The rate of contraction slowed down to 48 h and no further significant contraction observed to 96 h.
Weave-like collagen arrangement observed
in CTGF siRNA/KALA nanocomplex-treated wound Figure 3A shows histology of normal skin which shows well-developed epidermis and dermal collagen matrix (arrow) and basement membrane (arrow) between dermalepidermal junctions. A typical basket weave-like pattern of collagen arrangements were observed. Figure 3B shows histologic cross-section of mismatch siRNA/KALA-treated 8 mm full thickness surgical wound at 61 day post wounding time: dense and parallel abnormal arrangements of collagen fibrils observed (indicated as an arrow); damaged cartilage (arrow) has not been repaired yet (hematoxylin & eosin stain, x100 and x200). Figure 3C shows the histology of 61 day post injury after treatment of siRNA/ KALA. Collagen fibril bundles arranged in a basket weave pattern similar to normal dermis were observed.
Collagen fibril diameter and organization were analyzed by TEM
Ultra-structural collagen organization was examined as an indication of the quality of the scar tissue. The relative frequences within a specific range of diameters were evaluated and a histogram to demonstrate the differences in the disposition of collagen fibril diameters was prepared. Figure 4A shows strong well developed collagen fibrils in dermal matrix of rabbit ear skin. The interwoven organization is the key to a functional connective tissue matrix. In normal skin, the extracellular matrix was made of collagen fibril bundles organized in a basket weave pattern. Normal skin contained relatively large collagen with average diameter 318 ± 109 nm (n = 172). Scar is composed of densely packed, disorganized collagen fiber bundles. An impaired collagen fibril organization with fibril bundles oriented parallel to each other in contrast with a basket weave pattern arrangement in normal skin are typical characterization of scar tissue [19, 20] . Figure 4B shows a parallel arrangement of collagen bundles in 61 day post 8 mm full thickness b Fig. 1 A Effect of CTGF siRNA/MPG DNLS ratio (1:1-1:24) on down-regulation of CTGF in fibroblast wound model: mismatch siRNA was served as a negative control and Lipofectamine was served as a positive control. CTGFsiRNA/MPG DNLS showed no significant silencing effect on CTGF level. B Effect of CTGF siRNA/ KALA ratio (1:1-1:24) on down-regulation of CTGF expression in fibroblast wound model. CTGFsiRNA/KALA showed 40-60% downregulation of CTGF at 1:12 and 1:24 ratios. (*denotes statistically different from control, p \ 0.01) wounding after mismatch siRNA/KALA-treated wound. Parallel collagen fibril arrangement is a characteristic of scar tissue and causes the matrix to retract and harden. Scar tissue from mismatch siRNA/KALA-treated wound contained a high frequency of very small diameter fibrils. This fibril diameter is significantly lower than that of normal skin; with average diameter 90 ± 20 nm (n = 563). Figure 4C shows TEM of CTGF siRNA/KALA-treated wound at 61 day post wounding. It shows extracellular matrix was made of collagen fibril bundles organized in a basket weave pattern.
CTGF siRNA/KALA-treated wound showed well developed collagen arrangements with the mean diameter of 128 ± 22 nm (n = 821).
Discussion
Collagen remodeling occurs during wound healing. Regulation of collagen synthesis and disposition is an efficient approach to control scar tissue formation [23] . Cell penetrating peptides (CPPs) such as KALA and MPG DNLS with siRNA complexes were prepared and the down-regulation of CTGF and its effect on the collagen lattice contraction rate were investigated. In this investigation, as a vector to deliver siRNA into the cytosol, fusion peptides KALA and MPG DNLS were investigated. In 1997, Szoka group at UCSF proposed a low-molecular weight cationic amphipathic peptide KALA that binds to DNA, destabilizes membranes, and mediates DNA transfection [24] . KALA has been recognized for its membrane disrupting property: KALA enters the endosomal pathway and then disrupt the acidic compartment and introduce siRNA into the cytoplasm prior to fusion of the endosome with the lysosome [25] . MPG peptide derived from the fusion peptide of HIV-1 gp41 protein is a 27-residue-long primary amphipathic peptide contains the fusion sequence, nuclear localizing sequence and linker domain. MPG carries a cysteamide group at its C-terminus, which is essential for both cell entry and stabilization of the complexes with siRNA. A single mutation on the second lysine residue of the NLS to serine (MPG DNLS ) could abolish the nuclear translocation and facilitate a rapid release of the siRNA in the cytoplasm [17] . MPG DNLS lysine at 18th amino acid replaced with serine residue for an enhanced cytosolic delivery was investigated for its CTGF down-regulation efficacy.
In this study, fusion peptide KALA could form CTGF siRNA complexes and down-regulate CTGF level to 40-60% as compared with control values (mismatch siRNA/Lipofectamine). However, CTGFsiRNA/MPG DNLS showed no statistically significant down-regulation of CTGF than those of Lipofectamine at either 1:12 or 1:24 ratio complexes. Inefficiency to down-regulate CTGF expression by CTGFsiRNA/MPG DNLS could be due to the difficulty of siRNA escaping from endosome or release siRNA from the siRNA-MPG 4NLS complexes [17] . Further study to verify this hypothesis should be performed. To analyze the effect of peptide-mediated down regulation of CTGF on full thickness wound healing process (0-61 day post injury time) focusing on collagen arrangement and fibril formation, we employed the rabbit ear model which permits a precise, reproducible, and more comprehensive analysis [14] . Histology and TEM analysis enabled us to understand the changes in the homogeneity of collagen fibril diameter in relation with scar prevention efficacy of CTGFsiRNA/KALA as compared with scrambled mismatch siRNA. Comparison of collage organization and fibril diameter in the tested tissues could be a critical parameter that evaluates the efficacy of scar preventive therapies.
In conclusion, CTGF siRNA/cell penetration peptide nanocomplexes were prepared. Peptide-mediated downregulation of CTGF by siRNA/KALA nanocomplexes modulated collagen fibril organization and diameter in fullthickness wound and showed comparable weave-like collagen arrangements like normal skin. This result suggests the potential application of CTGF siRNA/KALA nanocomplexes for anti-scar therapy. Further physicochemical characterization and formulation development including long-term stability in different storage condition is required for developing promising siRNA delivery medications [26, 27] .
